Stock 93M1 MPH HEALTH CARE AG
Add to a list
To use this feature you must be a member
Log inSign up

Ratings MPH Health Care AG Xetra

Equities

93M1

DE000A289V03

Real-time Estimate Tradegate
Other stock markets
 03:30:00 2024-06-27 EDT 		5-day change 1st Jan Change
27.1 EUR -0.37% Intraday chart for MPH Health Care AG -12.74% +64.56%
05-30 MPH Health Care AG Reports Earnings Results for the Full Year Ended December 31, 2023 CI
02-05 M1 Kliniken Mull Uplisting to Frankfurt Bourse's Prime Standard; Co-CEOs Buy 1.5 Million Shares MT

Strengths

  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • Given the positive cash flows generated by its business, the company's valuation level is an asset.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • Over the past four months, analysts' average price target has been revised upwards significantly.

Weaknesses

  • With an expected P/E ratio at 35.13 and 33.41 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
  • Over the past twelve months, analysts' consensus has been significantly revised downwards.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
MPH HEALTH CARE AG Stock MPH Health Care AG
+64.56% 125M - -
SUN PHARMACEUTICAL INDUSTRIES LTD. Stock Sun Pharmaceutical Industries Ltd.
+20.29% 43.67B
B-
OTSUKA HOLDINGS CO., LTD. Stock Otsuka Holdings Co., Ltd.
+26.21% 22.79B
B+
SANDOZ GROUP AG Stock Sandoz Group AG
+20.14% 15.45B -
CIPLA LIMITED Stock Cipla Limited
+17.95% 14.29B
B+
ZYDUS LIFESCIENCES LIMITED Stock Zydus Lifesciences Limited
+52.86% 12.83B
B
THE MEDICINES COMPANY Stock The Medicines Company
-0.05% 6.79B - -
ONO PHARMACEUTICAL CO., LTD. Stock Ono Pharmaceutical Co., Ltd.
-11.88% 6.52B
B+
ASPEN PHARMACARE HOLDINGS LIMITED Stock Aspen Pharmacare Holdings Limited
+12.62% 5.59B
B+
STADA ARZNEIMITTEL Stock STADA Arzneimittel
-8.87% 5.73B - -
Investor Rating
-
Trading Rating
-
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
-
Finances
-

Valuation

P/E ratio
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
  1. Stock Market
  2. Equities
  3. 93M1 Stock
  4. 93M1 Stock
  5. Ratings MPH Health Care AG